{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-065190","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.875436+00:00","generated_at":"2026-05-16T00:49:57.895946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M","bullets":["Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.","Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.","Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.","Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.","Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-065190","json":"https://secwatch.observer/filing/0001193125-26-065190.json","markdown":"https://secwatch.observer/filing/0001193125-26-065190.md","text":"https://secwatch.observer/filing/0001193125-26-065190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/0001193125-26-065190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526065190/fulc-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:49:57.895946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}